Compare Stocks: EDIT, BEAM, and TWST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.46 +0.6%	$29.45	$17.74 ▼ $38.26	$3.03B	2.22	1.57 million shs	1.27 million shs
EDIT Editas Medicine	$3.08	$3.02	$1.66 ▼ $4.54	$473.03M	2.09	2.67 million shs	1.38 million shs
TWST Twist Bioscience	$128.71 -1.7%	$110.41	$23.30 ▼ $155.44	$8.21B	2.22	1.68 million shs	1.07 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.58%	-3.35%	+3.92%	+0.20%	+57.04%
EDIT Editas Medicine	0.00%	-6.67%	+11.19%	+13.65%	+23.20%
TWST Twist Bioscience	-1.75%	-15.93%	+29.43%	+85.94%	+395.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.46 +0.6%	$29.45	$17.74 ▼ $38.26	$3.03B	2.22	1.57 million shs	1.27 million shs
EDIT Editas Medicine	$3.08	$3.02	$1.66 ▼ $4.54	$473.03M	2.09	2.67 million shs	1.38 million shs
TWST Twist Bioscience	$128.71 -1.7%	$110.41	$23.30 ▼ $155.44	$8.21B	2.22	1.68 million shs	1.07 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.58%	-3.35%	+3.92%	+0.20%	+57.04%
EDIT Editas Medicine	0.00%	-6.67%	+11.19%	+13.65%	+23.20%
TWST Twist Bioscience	-1.75%	-15.93%	+29.43%	+85.94%	+395.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	66.33% Upside
EDIT Editas Medicine	2.67	Moderate Buy	$5.80	88.31% Upside
TWST Twist Bioscience	2.70	Moderate Buy	$98.30	-23.63% Downside

Current Analyst Ratings Breakdown

Latest EDIT, BEAM, and TWST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/24/2026	TWST Twist Bioscience	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	TWST Twist Bioscience	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$85.00 ➝ $115.00
8/4/2026	TWST Twist Bioscience	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$113.00 ➝ $115.00
8/3/2026	TWST Twist Bioscience	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	TWST Twist Bioscience	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$110.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	21.78	N/A	N/A	$10.34 per share	2.85
EDIT Editas Medicine	$40.52M	11.67	N/A	N/A	$0.69 per share	4.46
TWST Twist Bioscience	$376.57M	21.43	N/A	N/A	$7.11 per share	18.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	11/13/2026 (Estimated)

Latest EDIT, BEAM, and TWST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
EDIT Editas Medicine	N/A	3.19	3.19
TWST Twist Bioscience	0.03	2.67	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
EDIT Editas Medicine	71.90%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
EDIT Editas Medicine	3.10%
TWST Twist Bioscience	3.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
TWST Twist Bioscience	990	62.71 million	60.78 million	Optionable

EDIT, BEAM, and TWST Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Twist Bioscience Corporation $TWST

September 3 at 5:03 AM | marketbeat.com

Corient Private Wealth LP Invests $2.23 Million in Twist Bioscience Corporation $TWST

September 3 at 3:59 AM | marketbeat.com

Susquehanna Fundamental Investments LLC Takes Position in Twist Bioscience Corporation $TWST

September 1 at 5:51 AM | marketbeat.com

Jupiter Topco LLC Makes New Investment in Twist Bioscience Corporation $TWST

September 1 at 4:55 AM | marketbeat.com

121,980 Shares in Twist Bioscience Corporation $TWST Acquired by Legal & General Group Plc

September 1 at 4:48 AM | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Acquires New Position in Twist Bioscience Corporation $TWST

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $19.72 Million in Twist Bioscience Corporation $TWST

August 31, 2026 | marketbeat.com

Man Group plc Invests $6 Million in Twist Bioscience Corporation $TWST

August 30, 2026 | marketbeat.com

Emily Leproust Sells 41,570 Shares of Twist Bioscience (NASDAQ:TWST) Stock

August 29, 2026 | americanbankingnews.com

Twist Bioscience Slides as Investors Appear to Cool on Recent AI-Fueled Rally

August 28, 2026 | quiverquant.comQ

Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 41,570 Shares of Stock

August 28, 2026 | insidertrades.com

Twist Bioscience (NASDAQ:TWST) CEO Sells 41,570 Shares

August 27, 2026 | marketbeat.com

Odyssean LLC Purchases Shares of 26,232 Twist Bioscience Corporation $TWST

August 26, 2026 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Hits New 1-Year High - Still a Buy?

August 25, 2026 | marketbeat.com

Osterweis Capital Management Inc. Buys Shares of 111,458 Twist Bioscience Corporation $TWST

August 25, 2026 | marketbeat.com

Quantbot Technologies LP Purchases New Stake in Twist Bioscience Corporation $TWST

August 25, 2026 | marketbeat.com

Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWST

August 25, 2026 | marketbeat.com

23,800 Shares in Twist Bioscience Corporation $TWST Bought by Maxi Investments CY Ltd

August 24, 2026 | marketbeat.com

Ieq Capital LLC Invests $5.26 Million in Twist Bioscience Corporation $TWST

August 24, 2026 | marketbeat.com

90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AG

August 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EDIT, BEAM, and TWST Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$29.46 +0.17 (+0.58%)

As of 09/3/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Editas Medicine NASDAQ:EDIT

$3.08 0.00 (0.00%)

As of 09/3/2026 04:00 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Twist Bioscience NASDAQ:TWST

$128.71 -2.29 (-1.75%)

As of 09/3/2026 04:00 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDIT, BEAM, and TWST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDIT, BEAM, and TWST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDIT, BEAM, and TWST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EDIT, BEAM, and TWST Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Editas Medicine NASDAQ:EDIT

Twist Bioscience NASDAQ:TWST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDIT, BEAM, and TWST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDIT, BEAM, and TWST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDIT, BEAM, and TWST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EDIT, BEAM, and TWST Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Editas Medicine NASDAQ:EDIT

Twist Bioscience NASDAQ:TWST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools